Winter Has Come: Big Pharma Cold And Cough Sales Drop By Half Following New China Policy
This article was originally published in PharmAsia News
Executive Summary
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
You may also be interested in...
China's OTC Market: Cardiovascular Are Highly Concerned And Cold And Cough Remains The Most Common Health Issue
SHANGHAI - China's over-the-counter drug market has grown 10 to 15 percent since 2007 and to more than RMB 90 billion ($13 billion) in 2009, according to healthcare market intelligence provider IMS Health
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
CROs At Risk From China’s New Inventor Regulation?
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.